‘Bubble effect’: Weight loss drug fueled growth is putting the pharma sector at risk, report finds
Obesity assets represent about 25% of total forecast sales of the late-stage pipeline, while oncology’s share has slipped to 20%, Deloitte found.
原文: https://www.cnbc.com/2026/05/04/wegovy-glp1-weight-loss-drugs-pharma-growth-bubble.html
Last Update:
4 5 月, 2026